DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

October 6, 2023

Study Completion Date

December 1, 2023

Conditions
Staphylococcal Bacteraemia
Interventions
DRUG

Cefazolin

Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)

DRUG

Dalbavancin

A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species

DRUG

Daptomycin

Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks

DRUG

Nafcillin

Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)

DRUG

Oxacillin

Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks

DRUG

Vancomycin

Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)

Trial Locations (24)

13210

SUNY Upstate Medical University - Infectious Disease Division, Syracuse

15213

University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh

22612

University of South Florida Health - Internal Medicine, Tampa

24014

Carilion Roanoke Memorial Hospital, Roanoke

27157

Wake Forest Baptist Medical Center, Winston-Salem

27710

Duke University Hospital - Infectious Diseases, Durham

28209

Atrium Health ID Consultants & Infusion Care Specialists, Charlotte

29605

Prisma Health - Greenville Health System - Infectious Disease, Greenville

32610

University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville

35233

University of Alabama Hospital - Infectious Diseases, Birmingham

60612

Rush University Medical Center, Chicago

70121

Ochsner Health - Ochsner Medical Center - Department of Infectious Diseases, New Orleans

90505

Torrance Memorial Medical Center, Torrance

95817-1460

University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento

90502-2006

Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance

48202-2608

Henry Ford Health System - Henry Ford Hospital, Detroit

48073-6757

Corewell Health - Infectious Disease, Royal Oak

68198-5400

University of Nebraska Medical Center - Infectious Diseases, Omaha

08244

South Jersey Infectious Disease, Somers Point

10065-4870

New York Presbyterian Hospital - Weill Cornell Medical Center - Infectious Diseases, New York

27834-9997

East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic, Greenville

97239-3098

Oregon Health and Science University - Adult Infectious Diseases Clinic, Portland

77030-4000

The University of Texas - MD Anderson Cancer Center - Infectious Diseases, Houston

Unknown

McGill University Health Centre, Montreal

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH